Orelabrutinib
Jump to navigation
Jump to search
Clinical data | |
---|---|
Trade names | 宜诺凯 |
Other names | ICP-022; ICP022 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C26H25N3O3 |
Molar mass | 427.504 g·mol−1 |
3D model (JSmol) | |
| |
|
Orelabrutinib is a drug for the treatment of cancer.
In China, it is approved for patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), who have received at least one treatment in the past.[1]
Orelabrutinib is an inhibitor of Bruton's tyrosine kinase.[2]
References
- ^ Dhillon S (March 2021). "Orelabrutinib: First Approval". Drugs. 81 (4): 503–507. doi:10.1007/s40265-021-01482-5. PMID 33704654.
- ^ Deng LJ, Zhou KS, Liu LH, Zhang MZ, Li ZM, Ji CY, et al. (August 2023). "Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study". Blood Advances. 7 (16): 4349–4357. doi:10.1182/bloodadvances.2022009168. PMC 10432605. PMID 37078706.
Categories:
- Articles with short description
- Short description with empty Wikidata description
- Drugs with non-standard legal status
- Infobox drug articles with non-default infobox title
- Articles without KEGG source
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- All stub articles
- Antineoplastic and immunomodulating drug stubs
- Antineoplastic and immunomodulating drugs
- Diphenyl ethers
- Acrylamides
- Piperidines
- Pyridines
- Carboxamides
- Kinase inhibitors